DaiChiharaMDPhD

Hematologic Oncology

Assistant Professor

Dr. Chihara is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Dr. Dai Chihara is an oncologist in Houston, TX and is affiliated with University of Texas M.D. Anderson Cancer Center. He received his medical degree from Kobe University Faculty of Medicine and has been in practice 18 years. He specializes in lymphoma. He has more than 100 publications and over 2000 citings.

National Institutes of Health Clinical CenterFellowship, Medical Oncology, 2018 - 2020
University of New Mexico School of MedicineResidency, Internal Medicine, 2016 - 2018
Kobe Univ- Fac MedClass of 2004
Nagoya UniversityPh.D.

Abstract achievement award ASH, 2020
Outstanding Academic Achievement Award National Cancer Institute, 2020
Bradley Stuart Beller Endowed Merit Award American Society of Clinical Oncology, 2019
House Officer Research Award University of New Mexico, 2018
Next Generation Leadership Award naisA, 2018
Abstract achievement award American Society of Hematology, 2017
Fellow excellence award for professionalism MD Anderson Cancer Center, 2016
Best research fellow in Leukemia MD Anderson Cancer Center, 2016
The Kimberly Patterson fellowship in Leukemia research MD Anderson Cancer Center, 2016
The Janice Davis Singletary Lymphoma fellowship award MD Anderson Cancer Center, 2015
ASCO Merit award American Society of Clinical Oncology, 2015
ASH abstract achievement award American Society of Hematology, 2010, 2015
PanPacific Lymphoma Conference travel award PanPacific Lymphoma Conference, 2014
Young Investigators Award Japanese Society of Hematology, 2013
12th International Conference of Malignant Lymphoma travel award ICML, 2013
Join now to see all

PubMed

20 citations
The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma.
Dai Chihara, Graça M. Dores, Christopher R. Flowers, Lindsay M. Morton
Blood. 2021-09-02
236 citations
Differences in incidence and trends of haematological malignancies in Japan and the United States
Dai Chihara, Hidemi Ito, Tomohiro Matsuda, Akiko Shibata, Akira Katsumi
British Journal of Haematology. 2014-02-01
13 citations
Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006
Dai Chihara, Hidemi Ito, Koji Izutsu, Masakazu Hattori, Yoshikazu Nishino
International Journal of Cancer. 2015-09-01

Lectures

Randomized phase II study of cladribine with simultaneous or delayed rituximab in patients with untreated hairy cell leukemia.
ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019